Portfolio map · VC firm · United States
Omega Funds portfolio map
57 startups Omega Funds has backed in rounds we track, since 2007, grouped by their main sector. Together they have raised $9.6B; Omega Funds led at least one round in 7 of them. The biggest sector is Biotech, with 47 companies.
Biotech
47
Intarcia Therapeutics
Nuvation Bio
Gossamer Bio
Trevi Therapeutics
Windward BioAlumis
Editas Medicine
Morphic Therapeutic
Beam Therapeutics
Beta Bionics- CPCinCor Pharma
Arcutis Biotherapeutics
Upstream Bio
Alpine Immune Sciences
Alveus Therapeutics Inc.
Marea Therapeutics
Callio Therapeutics
Senti Biosciences
Alleviant Medical
Scorpion Therapeutics
Replimune Group
Endeavor BioMedicines
ARTBIO
Vanqua Bio
+23 more
Funding by segment
- Biotech$8.7B47
- Healthtech$441M5
- Pharma$484M5
Where they are based
- United States44$8.6B
- United Kingdom3$191M
- Switzerland2$415M
- Spain1$73M
- Belgium1$39M
- Canada1$29M
- Finland1$3.4M
- Germany1$113M
United States
United Kingdom
Switzerland
Spain
Belgium
Canada
Finland
GermanyFounded
6 without a founding year on record.
Total raised
- Under $1M0
- $1M to $10M2
- $10M to $50M7
- $50M to $250M37
- $250M to $1B10
- $1B and over1
Each dot is a startup: the year it was founded across, the total it has raised up (each line is ten times the one below). Pick a segment to pick it out.
50 of 57 startups shown; the rest have no founding year or amount on record.
- 1 to 2
- 3 to 7
- 8 to 24
- 25 to 99
- 100 and more
- United States44
- United Kingdom3
- Switzerland2
- Spain1
- Belgium1
- Canada1
- Finland1
- Germany1
Startups by country, 8 countries in all.
Segment by segment
Biotech
47 startups · $8.7B raised
- Intarcia TherapeuticsIntarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.United States$1.1B
- Nuvation BioNuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.United States$675M
- Gossamer BioGossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.United States$567M
- Trevi TherapeuticsTrevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.United States$386M
- Windward BioWindward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committedSwitzerland$365M
- Editas MedicineEditas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.United States$335M
- Morphic TherapeuticMorphic Therapeutic is a biotechnology company that develops oral integrin therapies to treat serious chronic diseases.United States$328M
Healthtech
5 startups · $441M raised
Kestra Medical Technologies, Inc.Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.United States$138M
JenaValve TechnologyJenaValve is a medical device company focused on the design and development of innovative transcatheter heart valve solutionsGermany$113M
Kezar Life SciencesKezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disordeUnited States$85M
SoniVieSoniVie Ltd develops an advanced denervation solution-$60M
XII MedicalXII Medical is a clinical-stage medical technology company based in Union City, California, founded in 2017.United States$45M
Pharma
5 startups · $484M raised
Antares TherapeuticsAntares Therapeutics, Inc.United States$177M
Protego BiopharmaProtego Biopharma is a California-based biotechnology company that researches and develops small-molecule therapeutics for the treUnited States$130M
NRG TherapeuticsNRG Therapeutics Ltd is a private biotechnology company focused on drug discovery for neurodegenerative disorders.United Kingdom$79M
Spruce BiosciencesSpruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.United States$60M
Caldera TherapeuticsCaldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).United States$38M
How this map is made. Every startup here has raised money in a round we track that names Omega Funds as an investor, the first in 2007. Each sits under its main sector, read from its rounds, and each sector shows its best-funded first; sectors with fewer than three companies are left off. Rebuilt nightly; updated 15 November 2026.
More portfolio maps
All portfoliosRaising from investors like Omega Funds?
Find the investors who back startups like yours, with their cheques, rounds and partners, in the app with filters, lists and exports.